modelGoserelin
Extends from Pharmacolibrary.Drugs.ATC.L.L02AE03.
Information
| name: | Goserelin | |
| ATC code: | L02AE03 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 3.6 | mg |
| volume of distribution: | 44.1 | L |
| clearance: | 15.8 | L/h |
| other parameters in model implementation | ||
Goserelin is a synthetic decapeptide analogue of luteinizing hormone-releasing hormone (LHRH, also known as GnRH) used as a gonadotropin-releasing hormone agonist. It causes a reversible suppression of gonadal steroidogenesis and is indicated mainly in the treatment of hormone-sensitive cancers such as prostate cancer in men and breast cancer in premenopausal women, as well as in some cases of endometriosis. Goserelin is approved and widely used today.
Pharmacokinetics
Healthy male volunteers, pharmacokinetics after subcutaneous administration of goserelin (standard clinical dosing regimen).
References
Cheer, SM, et al., & Wagstaff, AJ (2005). Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs 65(18) 2639–2655. DOI:10.2165/00003495-200565180-00011 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16392882
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)